

Miraculins Named Manitoba Life Science Company of the Year

WINNIPEG, Manitoba – February 4, 2013 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that it will receive the Life Science Company of the Year Award from the Life Science Association of Manitoba at an awards ceremony on February 13, 2013. The award is presented annually to a private sector company based in Manitoba that has made a positive impact on the life sciences sector in the past year and is active in paving the road toward future wealth and job creation in the province. Past Life Science Company of the Year Award winners include IMRIS, Biovail and Cangene.

The Life Science Association of Manitoba (LSAM) presents its annual Life Science Awards as a way to recognize the leaders and innovators of the life science community. With its selection as Life Science Company of the Year, Miraculins has been recognized for distinguishing itself from its peers with strong overall company performance, demonstrating leadership and showing significant achievement.

“We are pleased to acknowledge Miraculins as the Life Science Company of the Year for 2012,” said Tracey Maconachie, President of LSAM. “The life science industry in Manitoba, which now accounts for 7% of the province’s GDP, is loaded with exceptional companies, with Miraculins serving as a prime example of the type of burgeoning life science success stories that Manitoba is offering the world.”

“We are honoured to have been recognized by LSAM for our accomplishments to date, and for our potential as we move forward,” said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. “We are proud to share news of this award with our shareholders, investors and customers, without whom we would not have been able to reach this point in our corporate development. Furthermore, we are pleased to be acknowledged amongst the many deserving life science companies in Manitoba, and are proud to be a part of this important sector, with a very supportive industry association and a provincial government with a true appreciation for innovation.”

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company’s PreVu[®] technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient’s skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company’s preeclampsia program is partnered with Alere Inc., one of the world’s largest diagnostic companies. For more information visit www.miraculins.com.

About LSAM

LSAM is the voice and organizational nucleus for the life science industry of Manitoba.

This innovative industry, which now accounts for nearly 7% of Manitoba's GDP, is extremely diverse and wide-reaching. The industry's core businesses can be grouped into three distinct categories: agriculture and food products, health products and industrial bio-products.

LSAM focuses on attentive, proactive and timely services and programs to over 100 member organizations. It constantly strives to understand which products, services and support its members value most, and creates partnerships and programs to deliver them.

LSAM's activities are focused on four key areas:

- To be a connector for people, information and ideas;
- To support the development of Manitoba's human resource capacity;
- To strengthen the business environment for members; and
- To provide a strong voice for the life science industry in Manitoba.

For more information go to www.lsam.ca.

For more information, please contact:

Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph. 204-477-7599
Fax: 204-453-1546

info@miraculins.com
www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential

product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

PreVu[®] is a registered trademark of Miraculins Inc. All Rights Reserved. 2013.